A multicenter, prospective, real-world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice (PIONEER REAL Japan): Subgroup analyses.

ABSTRACT:

Aims

HbA_1c and body weight were assessed across selected subgroups of adults with type 2 diabetes receiving oral semaglutide in clinical practice.

Methods

In this non-interventional study, changes in HbA_1c and body weight to end of study (EoS) and safety were assessed by subgroup: baseline age, body mass index (BMI), type 2 diabetes duration, participants switching from dipeptidyl peptidase-4 inhibitors, and semaglutide dose at EoS.

Results

All subgroups experienced reductions in HbA_1c and body weight. Younger participants had greater reductions in HbA_1c than older participants (-0.9, -0.7, -0.7, and -0.5 percentage points for participants aged <55, ≥55-<65, ≥65-<75, and ≥75 years, respectively [P = 0.0467]). Shorter type 2

SUBMITTER: Yabe D 

PROVIDER: S-EPMC12489328 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature